Down-regulation of MIAT suppresses osteosarcoma progression by acting as a ceRNA for miR-141-3p to regulate SIX1-mediated PI3K/AKT pathway

被引:12
作者
Ji, Q. [1 ]
Zhu, J. [2 ]
Fang, C-L [3 ]
Jin, H. [2 ]
Zhan, D-P [2 ]
Huang, J. [1 ]
机构
[1] Huishan Dist Peoples Hosp, Dept Orthopaed, Wuxi, Jiangsu, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Orthopaed, Harbin, Peoples R China
[3] Xinxiang Med Univ, Clin Med, Xinxiang, Henan, Peoples R China
基金
中国国家自然科学基金;
关键词
Osteosarcoma; MIAT; SIX1; PI3K/AKT pathway; miR-141-3p; NONCODING RNA MIAT; CELL LUNG-CANCER; INHIBITS PROLIFERATION; PROMOTES APOPTOSIS; EXPRESSION; SIX1; METASTASIS; INVASION; GROWTH; MIGRATION;
D O I
10.26355/eurrev_202003_20487
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Osteosarcoma (OS) is a frequent bone malignancy. Long non-coding RNA myocardial infarction associated transcript (MIAT) has been reported to be involved in the development of human cancers. including OS. However. the mechanism underlying MIAT in OS progression remains largely unclear. PATIENTS AND METHODS: The expression levels of MIAT and sineoculis homeobox homolog 1 (SIX1) in OS tissues and cells were detected by quantitative real-time polymerase chain reaction and Western blot. Cell viability, apoptosis. migration and invasion of OS cells were determined by MTT, flow cytometry and transwell assays, respectively. The target interaction among MIAT, miR-141-3p and SIX1 was analyzed by bioinformatics analysis and luciferase reporter assay. Phosphatidylinositide 3-kinases (PI3K)/protein kinase B (AKT) pathway was evaluated by Western blot. RESULTS: MIAT and SIX1 expression levels were enhanced in OS tissues and cells. Knockdown of MIAT or SIX1 repressed cell viability. migration and invasion but promoted apoptosis in OS cells. Moreover. overexpression of SIX1 reversed the inhibitive role of MIAT silence in OS progression. Furthermore, MIAT could increase SIX1 expression by competitively sponging miR-141-3p. Besides, inhibition of MIAT blocked PI3K/AKT pathway by decreasing SIX1 in OS cells. CONCLUSIONS: MIAT silence suppresses OS progression through inactivating PI3K/AKT signaling by sponging miR-141-3p to regulate SIX1, indicating a novel target for the treatment of OS.
引用
收藏
页码:2218 / 2228
页数:11
相关论文
共 35 条
[1]   Noncoding RNA:RNA Regulatory Networks in Cancer [J].
Chan, Jia Jia ;
Tay, Yvonne .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (05)
[2]   Increased Six1 expression is associated with poor prognosis in patients with osteosarcoma [J].
Chao, Lemeng ;
Liu, Jianfeng ;
Zhao, Dewei .
ONCOLOGY LETTERS, 2017, 13 (05) :2891-2896
[3]   RETRACTED: MicroRNA-191-5p promotes the development of osteosarcoma via targeting EGR1 and activating the PI3K/AKT signaling pathway (Retracted article. See vol. 25, pg. 3145, 2021) [J].
Chen, B. ;
Zheng, Z-Y ;
Yang, J-Z ;
Li, X-G .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (09) :3611-3620
[4]   Silencing of Long Non-coding RNA MIAT Sensitizes Lung Cancer Cells to Gefitinib by Epigenetically Regulating miR-34a [J].
Fu, Yunfeng ;
Li, Chengyuan ;
Luo, Yanwei ;
Li, Lian ;
Liu, Jing ;
Gui, Rong .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[5]  
He R, 2018, EUR REV MED PHARMACO, V22, P5857, DOI 10.26355/eurrev_201809_15915
[6]   lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214 [J].
Huang, Xinli ;
Gao, Yun ;
Qin, Jianjie ;
Lu, Sen .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2018, 314 (05) :G559-G565
[7]   Osteosarcoma: Current Treatment and a Collaborative Pathway to Success [J].
Isakoff, Michael S. ;
Bielack, Stefan S. ;
Meltzer, Paul ;
Gorlick, Richard .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (27) :3029-U127
[8]   Long non-coding RNA MIAT competitively binds miR-150-5p to regulate ZEB1 expression in osteosarcoma [J].
Jin, Hao ;
Jin, Xin ;
Chai, Weiguang ;
Yin, Zhiqiang ;
Li, Yang ;
Dong, Feng ;
Wang, Wenbo .
ONCOLOGY LETTERS, 2019, 17 (01) :1229-1236
[9]   The interaction of long non-coding RNA MIAT and miR-133 play a role in the proliferation and metastasis of pancreatic carcinoma [J].
Li, Ting-Fu ;
Liu, Jian ;
Fu, Shi-Jie .
BIOMEDICINE & PHARMACOTHERAPY, 2018, 104 :145-150
[10]  
Li YM, 2019, EUR REV MED PHARMACO, V23, P4688, DOI 10.26355/eurrev_201906_18050